Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • AUD/USD

    0.6494
    -0.0042 (-0.64%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    81.74
    +0.39 (+0.48%)
     
  • GOLD

    2,215.90
    +3.20 (+0.14%)
     
  • Bitcoin AUD

    108,674.69
    +1,564.58 (+1.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor

Shares of BridgeBio Pharma, Inc. BBIO were up 14% on Thursday May 12, after management announced that BBIO has inked an exclusive licensing deal with Bristol Myers BMY to develop and commercialize its SHP-2 inhibitor BBP-398, targeting oncology indications.

Per the terms of the agreement, BridgeBio will receive $90 million as an upfront payment from Bristol Myers. BBIO is also eligible to receive up to $815 million of potential milestones as well as tiered royalties in low-to-mid teens.

In addition, BridgeBio will have an option to receive higher royalties on U.S. sales of the drug, provided it funds a portion of development costs upon initiation of registrational studies.

BridgeBio is currently evaluating BBP-398 in three phase I monotherapy and combination studies on solid tumors. While BBIO will continue to lead the ongoing phase I studies on BBP-398, Bristol Myers will lead as well as fund all the future clinical studies evaluating the candidate.

ADVERTISEMENT

Shares of BridgeBio have plunged 64.4% in the year so far compared with the industry’s 31.9% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

This licensing agreement between BridgeBio and Bristol Myers is an extension of the non-exclusive clinical collaboration contract signed by the two companies last July. Both companies had reached an agreement to study BBP398 in combination with Opdivo, Bristol Myers’ blockbuster PD-L1 inhibitor, for treating advanced solid tumors carrying KRAS mutations.

Earlier this January, BridgeBio also entered into a non-exclusive clinical collaboration with Amgen AMGN to evaluate the combination of BBP-398 with Amgen’s KRAS G12C inhibitor Lumakras in patients with KRAS G12C-mutated advanced solid tumors. Per the agreement terms, BBIO will be responsible for sponsoring the study, while Amgen will be in charge of the worldwide supply of Lumakras.

Currently, BBIO has more than 30 programs in its pipeline and multiple ongoing clinical studies. Most of these pipeline programs are a result of its tie-ups with academic institutions and industry partners.

More than two-third of BridgeBio’s pipeline programs are in collaboration with the leading academic institutions like Columbia University, University of Texas and Standford University. The milestone fees received from Bristol Myers will help BBIO fund these programs, thereby enabling it to develop its pipeline.

BridgeBio Pharma, Inc. Price

BridgeBio Pharma, Inc. Price
BridgeBio Pharma, Inc. Price

BridgeBio Pharma, Inc. price | BridgeBio Pharma, Inc. Quote

Zacks Rank & Stock to Consider

BridgeBio currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Alkermes ALKS, which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 14.2% year to date.

Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

Alkermes plc (ALKS) : Free Stock Analysis Report

BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research